{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red80\green80\blue80;
\red37\green37\blue37;
\red21\green137\blue21;
\red119\green119\blue119;
\red204\green204\blue204;
\red255\green255\blue102;
\red14\green86\blue140;
\red246\green246\blue246;
\red247\green247\blue247;
\red61\green61\blue61;
\red33\green33\blue33;
\red238\green238\blue238;
\red20\green93\blue164;
\red107\green107\blue106;
\red249\green250\blue251;
\red228\green231\blue232;
\red51\green51\blue51;
\red187\green187\blue187;
\red254\green254\blue0;
\red56\green124\blue43;
\red151\green151\blue151;
\red233\green233\blue233;
\red181\green79\blue104;
\red112\green112\blue112;
\red0\green114\blue54;
\red106\green144\blue39;
\red239\green122\blue2;
\red232\green233\blue232;
\red249\green249\blue249;
\red204\green255\blue255;
\red223\green223\blue223;
\red239\green239\blue239;
\red183\green242\blue206;
\red255\green255\blue174;
\red214\green9\blue9;
\red255\green248\blue96;
\red240\green240\blue240;
\red105\green105\blue105;
\red227\green227\blue227;
\red33\green74\blue204;
\red188\green41\blue30;
\red190\green237\blue228;
\red214\green214\blue214;
\red242\green242\blue242;
\red236\green236\blue236;
\red255\green255\blue198;
\red172\green172\blue172;
\red9\green56\blue84;
\red203\green203\blue203;
\red245\green245\blue245;
\red229\green243\blue255;
\red179\green218\blue255;
\red127\green127\blue127;
\red71\green120\blue194;
\red255\green210\blue183;
\red120\green162\blue47;
\red251\green252\blue255;
\red102\green0\blue102;
\red182\green231\blue243;
\red185\green185\blue185;
\red218\green218\blue218;
\red190\green190\blue252;
\red240\green248\blue255;
\red118\green118\blue118;
\red221\green195\blue236;
\red61\green61\blue60;
\red89\green89\blue89;
\red86\green86\blue86;
\red16\green58\blue89;
\red255\green204\blue153;
\red23\green94\blue146;
\red149\green246\blue220;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 sans-serif;}{
\f4 georgia;}{
\f5 serif;}{
\f6 Source Sans Pro;}{
\f7 Helvetica;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj \paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
ThermoLife International, LLC v. Hi-Tech Pharmaceuticals, Inc., Not Reported in Fed....
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
}\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 89504e470d0a1a0a0000000d494844520000004e0000000a08030000002dbd985500000300504c5445f8a969f6913ff68931fff9f5f69241f5852af68d38fcddc4f58326fac294f8a868fac193fcdabefab985fcdfc7fef5eef58022f8a35efef6effde5d2fac092fffaf6f9ac6ffffcfafde8d7fef7f1f9b279f6862cf8aa6af79e56f79c53f58327fef1e7fde3cefeeee2f9b076f79a4efef8f4f58123f58224f9ae72feefe4f58021f9ae71fac295fffaf7fcdabffef7f2f9af73f9b177f8ac6ef9b47cf8a15bf6872ef79648fef5edf9b278fcd9bdf9b782f9b57efbc89ffde3cffffefdf6872df8aa6bfcd6b8fac59af9b781fabc8bfffbf8fac091fac396fbceaaf8a461f68e39f6882ffabe8dfabf8ff9b884f79c52fdeadbfeede0f68c36f89f58fcdcc3fde0c9fef0e5fef3eaf68f3cfbcaa2f8a867f9b37afaba87f68b35fde7d6fabf90fffcfbfaba86fde7d5f6903efffdfcfef4ecf68f3bfde1cafcdfc6fbd1affbcea9fcd6b7f68a33f79444fbcba5f58429fcdec6f9af74f8a25df58428f7a461fef4edfdede0fde6d4fde7d4f9b680fbc69cfbc8a0f9b37bfac9a1f69240f79d54fcd4b4f9b883f68e3afef8f3fdebddfde2cbf7984cf8a35ff6882efef3ebf9bd8cfcd4b5feecdef8a562fde6d3fef9f4fcdbc1f9bc8afcd8bcf8ab6dfef8f2fcd7b9fffbf7feefe3f79546f8aa69f79f57fde1cbfcd3b3fcd2b1f8a25cfcd3b2fde2ccfac599fac397f9b379fcd8bbfbd2b0fef2e9fcd5b6fac79ef8a664f8a460f68a32fac090fffbf9fef2e8f8ab6cfde4d0f7994df6903df79749fffefcf79e55f8a766f8a059f68830f7974afde2cdfbcca6fabd8cf57f20ffffff000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000c5baaa8e000000bf74524e53ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff00456e8439000002804944415478da63dcc70001fef2931866b0be0cd2085114e5ff7ef72a0357d0a3a31cc2129ebb9f492a3e4b6eb8cb20913bb5c808a2f849bf610c438bf99a9917cf2a18092c7bf1a30a6a0a13946658f6af92e15352e52386af5d677ee5ff61618c5ca7c6b58921d6ecc47383e56a52b3181955bf2e3e01513b49bae7260383be8b048376a2e34786a3853761a6b0c018892b57313c48fa38834195c1cf94c16a3a03c3edad7c5f163030a8672bcc3afcf4251343639ef3ae2cb05afe384e9390352a0c320cbdf71f19b43d6690c7302e84e11383d28bff67bcba9a6e2831acd9c6e0d990fe70b74ae7d2a90c0cbbc36fbaef6660b80f55ba68e9d2d5a9ae0cdd2f341878be8b9c64f8cb701d660a733c9451af78704effa1c6b3536708cf2c9ffde7c78fcb9b16497b8acf3e3721061812bfde8433302c8d5a190152ca93f7d26df6796bff83310dbfe504de7f7ff9ec621c7ad8ade964d5f0f8162da4257e9da18c39434955602283a37fdaefde9cb30c686005c3a4c9a6d792186c6b665d8e54f97ae7c5badd189e65307c22395565fbc43fcc010cad5b3ba781c5363184af0bfa8530481844b84e65b87efde6bcb50c67d9dc36d4f6bf7aa6e4015700771dc3fd57751f183c97ecfe7f04c8b17e9f9fdfceb0e334c3ca37c16940feb644b09ad7e1aee90cdaaa9f1ca31ef6bd6478e2b43ba29f615fc7cf550c1861c720c2699619c930d362d55a060ff68e592f7d4eacd82df9eb3bd7bd387986ff73182d18183686ba2ff9f76ec59f909c2e83a8499dbbaaa404ecf8199cb8051e79627ad6fa4799360383602cd0bdcbdeb2fc6158debec577daf1a9076ba51818e679bf05aaf85cfdeb0f8383c1ec0973801cee342386c537cdf218fecf4b70801b0200f61ff095f54de6170000000049454e44ae426082}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_50}{\*\bkmkend co_document_50}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart I6dfffa101ca311e9aec5b23c3317c9c0_Target}{\*\bkmkend I6dfffa101ca311e9aec5b23c3317c9c0_Target}
\par 
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb100 
2018 WL 7077163
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Only the Westlaw citation is currently available.
\par 
}
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States District Court, N.D. Georgia, Atlanta Division.
\par 
}
}
}
{\b0 \qc \cf20 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf20 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf20 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
THERMOLIFE INTERNATIONAL, LLC, Plaintiff,
\par 
}
}
{\b0 \qc \cf20 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf20 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
HI-TECH PHARMACEUTICALS, INC., et al., Defendants.
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1:15-CV-00892-ELR
\par 
}
}
}
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Signed 10/02/2018
\par 
}
}
}
}
{\b1 \cf29 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_50}{\*\bkmkend co_attorneysAndLawFirms_50}
{\b1 \cf29 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0263104101&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Nathaniel L. Dilger
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, One LLP, Newport Beach, CA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0493178599&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cammi Ryan Jones
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0328880901&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Thomas Charles Lundin, Jr.
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, FisherBroyles, LLP, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0443188101&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Jason Paul Grier
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0116174801&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Katrina M. Quicker
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Baker Hostetler, LLP, Atlanta, GA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0446765401&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Kalman Magyar
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Magyar & Bogle, Williamsville, NY, for Plaintiff.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0333456901&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Gregory L. Hillyer
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Hillyer Legal, PLLC, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0509837601&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Evi T. Christou
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Brinks Gilson & Lione, Washington, DC, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0254085901&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
John Thomas Gallagher
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Hoffmann & Baron, LLP, Syosset, NY, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0426141701&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cynthia Lynn Parker
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, CL Parker, LLC, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0124598401&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Arthur W. Leach
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Law Office of Arthur W. Leach, Alpharetta, GA, for Defendant Hi-Tech Pharmaceuticals, Inc.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0509837601&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Evi T. Christou
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Brinks Gilson & Lione, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0333456901&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Gregory L. Hillyer
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Hillyer Legal, PLLC, Washington, DC, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0124598401&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Arthur W. Leach
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Law Office of Arthur W. Leach, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0426141701&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cynthia Lynn Parker
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, CL Parker, LLC, Alpharetta, GA, for Defendant Jared Wheat.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0509837601&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Evi T. Christou
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Brinks Gilson & Lione, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0333456901&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Gregory L. Hillyer
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Hillyer Legal, PLLC, Washington, DC, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0124598401&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Arthur W. Leach
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Law Office of Arthur W. Leach, Alpharetta, GA, for Defendants Innovative Laboratories, Prime Nutrition, Advanced Performance.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0509837601&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Evi T. Christou
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Brinks Gilson & Lione, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0333456901&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Gregory L. Hillyer
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Hillyer Legal, PLLC, Washington, DC, for Defendant Supplements Nutrition.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf29 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_50}{\*\bkmkend co_opinion_50}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I0112dc6260c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I0112dc6260c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I011e270160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I011e270160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I011e270160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I011e270160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb800 
REPORT AND RECOMMENDATION TO DENY DEFENDANTS\rquote  MOTION TO DISMISS FOR FAILURE TO STATE A CLAIM AND DEFENDANTS\rquote  MOTION FOR ORAL ARGUMENT
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Anthony B. Askew, Esq., Special Master
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_1_50}{\*\bkmkend co_pp_sp_999_1_50}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Pending before the Court is Defendants\rquote  Motion to Dismiss for Failure to State a Claim (Dkt. No. 231). For the reasons discussed in this Report, it is recommended that the motion be DENIED.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Also pending before the Court is Defendants\rquote  Motion for Oral Argument (Dkt. No. 243). Pursuant to Civil Local Rule 7.1(E), this matter is suitable for decision without oral argument, and it is therefore recommended that the motion be DENIED.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I011ec34160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I011ec34160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I011ec34160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I011ec34160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
I. BACKGROUND
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I011ec34160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I011ec34160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
A. The Asserted Patents
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This case involves allegations of patent infringement concerning five related U.S. Patents (collectively, the \u8220\'3fAsserted Patents\u8221\'3f). The Asserted Patents include: 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027694181&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I887a68c09f4c11e1910adc00900fed44&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent Nos. 8,178,572 (\u8220\'3fthe \lquote 572 Patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027742370&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I3e30d940a43b11e1ba4083eae598aa4c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
8,183,288 (\u8220\'3fthe \lquote 288 Patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
8,455,531 (\u8220\'3fthe \lquote 531 Patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030808758&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=Ibd230671d88711e2a447f9a5042dbbad&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
8,466,187 (\u8220\'3fthe \lquote 187 Patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035430745&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=Iefc12300b27411e48d3ad255cfb4914b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
8,952,046 (\u8220\'3fthe \lquote 046 Patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (Dkt. No. 226, Exs. C, D, E, EE, and F.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
All five patents are continuing applications of a single parent application that matured into 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022784723&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I8b4fa0c1aa3e11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,777,074
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which is not asserted. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027694181&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I887a68c09f4c11e1910adc00900fed44&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 572 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027742370&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I3e30d940a43b11e1ba4083eae598aa4c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 288 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are continuations of the parent application and share the same specification. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030808758&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=Ibd230671d88711e2a447f9a5042dbbad&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 187 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035430745&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=Iefc12300b27411e48d3ad255cfb4914b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 046 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are continuation-in-part (CIP) applications from the parent application (or continuations thereof) and all share the same CIP specification.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Asserted Patents generally relate to compositions of various amino acids in combination with nitrates or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iab56f816475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
nitrites
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Asserted Patents also contain method claims where these compositions are administered to produce various effects including increased vasodilation, athletic performance, bioabsorption, solubility, and distribution of amino acids.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
According to the Background of the Asserted Patents, \u8220\'3f[i]t is desirable to design new amino acid compositions that have properties lacking in conventional amino acids, conventional nitrates, and conventional 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iab56f816475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
nitrites
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 alone.\u8221\'3f (Dkt. No. 226, Ex. D, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, col. 1, lns. 25-27.) Further, according to the specification of the Asserted Patents:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Applicants have discovered that the Creatine compound according to the third implementation, when ingested, provides enhanced 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c66e201475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Nitric Oxide
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (NO\u8212\'3f) production while providing improved vasodilation effects over single administration of Creatine, the single administration of Nitrates, or the single administration of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iab56f816475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Nitrites
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
. Improved vasodilation may, in turn, provide better circulation and distribution of Creatine in the body. Absorption may be improved since Amino Acid salts with inorganic acids are much more water soluble than single administration Amino Acids. Additionally a much lesser dose may be required for vasodilation to take place, compared to the single administration of nitrates.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
Enhancing a molecule\rquote s solubility can enhance it\rquote s bioavailability, rate of absorption by the [gastrointestinal] tract, and as a result, it\rquote s concentration in the muscle tissue and it\rquote s effectiveness. As we have established, the nitrate salts of creatine and other molecules are exceptionally more soluble that their counterparts. Recent studies on creatine nitrate show 1100% improved solubility over creatine monohydrate.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_2_50}{\*\bkmkend co_pp_sp_999_2_50}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*2
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, col. 19, lns. 18-37.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Finally, the patent specification further states that:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
Creatine Nitrate is the first creatine to solve to [sic] the solubility, stability, and dissolution challenges while simultaneously Providing up to 8 hours of powerful vasodilation that workout enthusiasts demand!
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, col. 23, lns. 7-10.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I0121f79160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I0121f79160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I0121f79160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I0121f79160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
B. Procedural History
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiff ThermoLife initiated this suit in March 2015 alleging that Defendants were infringing claims of the five Asserted Patents. (Dkt. No. 1.) The case was stayed pending the outcome of a number of reexaminations before the U.S. Patent Trial and Appeal Board involving the Asserted Patents. Upon resolution of the reexaminations, the stay was lifted, and Plaintiff filed its Second Amended Complaint in September 2017. (Dkt. No. 226.) In response, Defendants filed a Motion to Dismiss for Failure to State a Claim, pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Federal Rule of Civil Procedure 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (Dkt No. 231.) In their motion, Defendants contend that the claims of the Asserted Patents are directed to patent-ineligible subject matter and are therefore invalid, and thus all claims asserting infringement fail to state a claim under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In addition, Defendants filed a Motion for Oral Argument regarding their Motion to Dismiss. (Dkt No. 243.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I0122bae160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I0122bae160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I0122bae160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I0122bae160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
II. LEGAL STANDARDS
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I0122bae160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I0122bae160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
A. Motion to Dismiss Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Federal Rule of Civil Procedure 12(b)(6)
}}}
\sb200 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A complaint that falls short of the Rule 8(a) standard may be dismissed if it \u8220\'3ffail[s] to state a claim upon which relief can be granted.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Fed. R. Civ. P. 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR8&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Federal Rule of Civil Procedure 8(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 requires a plaintiff to plead each claim with sufficient specificity \u8220\'3fin order to give the defendant fair notice of what the ... claim is and the grounds upon which it rests.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012293296&pubNum=0000780&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_780_555&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_555" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bell Atl. Corp. v. Twombly
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 550 U.S. 544, 555, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (internal quotations omitted). The factual allegations in the complaint \u8220\'3fmust be enough to raise a right to relief above the speculative level\u8221\'3f such that the claim \u8220\'3fis plausible on its face.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012293296&pubNum=0000708&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_708_555&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_555" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 555, 570, 127 S.Ct. 1955
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
When deciding whether to grant a motion to dismiss, the court accepts as true all \u8220\'3fwell-pleaded factual allegations\u8221\'3f set forth in the complaint. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018848474&pubNum=0000780&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_780_664&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_664" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ashcroft v. Iqbal
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 556 U.S. 662, 664, 129 S.Ct. 1937, 173 L.Ed.2d 868 (2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017920578&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_506_958&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_958" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Wilchombe v. TeeVee Toons, Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 555 F.3d 949, 958 (11th Cir. 2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. However, \u8220\'3fcourts are not bound to accept as true a legal conclusion couched as a factual allegation.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018848474&pubNum=0000780&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_780_678&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_678" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Iqbal
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 556 U.S. at 678, 129 S.Ct. 1937
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Also, the court usually does not consider material beyond the pleadings for a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis. When a party moves to dismiss under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for failure to state a claim upon which relief can be granted, and introduces matters outside of the pleadings, the motion may instead be treated as if it were a motion for summary judgment under Rule 56. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2021614662&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_506_1337&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1337" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
SFM Holdings, Ltd. v. Banc of Am. Sec., LLC
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 600 F.3d 1334, 1337 (11th Cir. 2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. However, the Eleventh Circuit has instructed that a district court may consider extrinsic evidence in ruling on a motion to dismiss \u8220\'3fif it is (1) central to the plaintiff\rquote s claim, and (2) its authenticity is not challenged.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2021614662&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002482322&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_506_1267&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1267" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Trustmark Ins. Co. v. ESLU, Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 299 F.3d 1265, 1267-68 (11th Cir. 2002)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I0124ddc160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I0124ddc160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I0124ddc160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I0124ddc160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
B. Patent Eligibility at the Motion to Dismiss Stage
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_3_50}{\*\bkmkend co_pp_sp_999_3_50}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*3
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The ultimate question of whether a patent claim recites patent-eligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is a question of law. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041182286&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_506_1338&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1338" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Intellectual Ventures I LLC v. Capital One Fin. Corp.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 850 F.3d 1332, 1338 (Fed. Cir. 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fPatent eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is an issue of law[.]\u8221\'3f). However, the Federal Circuit has identified that there are certain factual questions underlying the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043776259&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_506_1368&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1368" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Berkheimer v. HP Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 881 F.3d 1360, 1368-69 (Fed. Cir. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Thus, while a district court may decide patent eligibility at the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 stage, the court may only conclude that a patent fails to claim patent-eligible subject matter \u8220\'3fwhen there are no factual allegations that, taken as true, prevent resolving the eligibility question as a matter of law.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043808569&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_506_1125&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1125" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Aatrix Software, Inc. v. Green Shades Software, Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 882 F.3d 1121, 1125 (Fed. Cir. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038639328&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_506_1373&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1373" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Genetic Techs. Ltd. v. Merial L.L.C.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 818 F.3d 1369, 1373 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I0125ef3160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I0125ef3160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I0125ef3160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I0125ef3160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
C. Patent Eligibility Under 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b1 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b1 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b1 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
: The 
}
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice/Mayo
}
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
 Framework
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8220\'3f[w]hoever invents or discovers any new and useful process, machine, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.\u8221\'3f However, the Supreme Court has recognized several judicial exceptions to these broad categories: \u8220\'3f[l]aws of nature, natural phenomena, and abstract ideas are not patentable.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_708_2116&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2116" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ass\rquote n for Molecular Pathology v. Myriad Genetics, Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. 576, 133 S.Ct. 2107, 2116, 186 L.Ed.2d 124 (2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_780_70&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_70" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Labs., Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. 66, 70, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
To determine whether a patent claim falls within the judicial exceptions to patent-eligible subject matter, the Supreme Court has established a two-step framework. First, the court must \u8220\'3fdetermine whether the claims at issue are directed to a patent-ineligible concept.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corp. Pty. Ltd. v. CLS Bank Int\rquote l
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 573 U.S. 208, 134 S.Ct. 2347, 2355, 189 L.Ed.2d 296 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Second, if the patent claims are directed to patent-ineligible subject matter, the court must \u8220\'3fconsider the elements of each claim both individually and \u8216\'3fas an ordered combination\u8217\'3f to determine whether the additional elements \u8216\'3ftransform the nature of the claim\u8217\'3f into a patent-eligible application.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_780_78&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_78" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Labs., Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. 66, 78, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). The Supreme Court has described this second step as a \u8220\'3fsearch for an \u8216\'3finventive concept\u8217\'3f\u8212\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, an element or combination of elements that is \u8216\'3fsufficient to ensure that the patent in practice amounts to significantly more than a patent upon the [ineligible concept] itself.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I012775d160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I012775d160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I012775d160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I012775d160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
III. ANALYSIS
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I012775d160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I012775d160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
A. Reliance on Extrinsic Evidence
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In support of their Motion to Dismiss for Failure to State a Claim, Defendants have provided several exhibits outside of the pleadings. (Dkt. No. 231, Exs. 2-9, 11, 13, 14.) The Parties dispute whether it is proper to consider these extrinsic materials at the motion to dismiss stage.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Eleventh Circuit has held that a district court may consider extrinsic evidence in a motion to dismiss \u8220\'3fif [the extrinsic evidence] is (1) central to the plaintiff\rquote s claim, and (2) its authenticity is not challenged.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2021614662&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_506_1337&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1337" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
SFM Holdings, Ltd. v. Banc of Am. Sec., LLC
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 600 F.3d 1334, 1337 (11th Cir. 2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999175850&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_506_802&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_802" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Harris v. Ivax Corp.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 182 F.3d 799, 802 n.2 (11th Cir. 1999)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (stating that \u8220\'3fa document central to the complaint that the defense appends to its motion to dismiss is also properly considered, provided that its contents are not in dispute.\u8221\'3f). (Dkt No. 242 at 2.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Defendants contend that the court may take notice of its extrinsic evidence because the evidence was limited to scholarly works and asserts that \u8220\'3fThermoLife has not challenged the authenticity of these materials.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 3.) While discovery has yet to take place, Defendants further assert that \u8220\'3f[n]o amount of discovery will transform ThermoLife\rquote s natural laws into patentable subject matter.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_4_50}{\*\bkmkend co_pp_sp_999_4_50}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*4
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Plaintiff contends that the Defendants \u8220\'3fpoint to nearly a dozen exhibits from outside the pleadings to support their factual assertions.\u8221\'3f (Dkt. No. 238 at 4.) Plaintiff further asserts that they have \u8220\'3fhad no opportunity to test the accuracy of the Defendants\rquote  evidence or present its own evidence.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiff rightly asserts that consideration of extensive materials outside of the pleadings is misplaced and premature at this stage in the pleadings. Accordingly, consideration of the additional exhibits provided by the Defendants, including scholarly articles, is not appropriate because the facts asserted in those documents could be disputed by the Plaintiff, if given the opportunity.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
When a party moves to dismiss under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for failure to state a claim upon which relief can be granted, and introduces matters outside of the pleadings, the motion may instead be treated as if it were a motion for summary judgment under Rule 56. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2021614662&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_506_1337&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1337" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
SFM Holdings, Ltd. v. Banc of Am. Sec., LLC
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 600 F.3d 1334, 1337 (11th Cir. 2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. However, conversion of the motion to dismiss to one for summary judgment is not appropriate at this time because the Plaintiff has not had an opportunity to present its evidence in response to that submitted by the Defendants. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033726621&pubNum=0007903&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_7903_1335&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_1335" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ralls Corp. v. Huerfano River Wind
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 27 F.Supp.3d 1303, 1335-36 (N.D. Ga. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (denying motion to dismiss that \u8220\'3fdepend[ed] on facts outside of the amended complaint and documents attached to [the] motion to dismiss\u8221\'3f and refusing to convert the motion to one for summary judgment); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009122646&pubNum=0000999&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Jane Doe No. 1 v. Fulton-DeKalb Hosp. Auth.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, No. 1:05-CV-2277-TWT, 2006 WL 1222289, at *2, 2006 U.S. Dist. LEXIS 28689 at *5-6 (N.D. Ga. May 3, 2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fDiscovery has not taken place, however, and the Plaintiffs have thus not had an opportunity to present all material pertinent to a motion for summary judgment.\u8221\'3f); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Charter Servs., Inc. v. D.L. Air., LLC
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, No. 09-0281-KD-N, 2009 U.S. Dist. LEXIS 102384, at *7 (S.D. Ala. Oct. 14, 2009). It is therefore recommended that the Court decline to convert the Defendants\rquote  motion to dismiss into a motion for summary judgment.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Defendants assert that whether or not the extrinsic materials are considered by the Court, \u8220\'3fthere is sufficient evidence in the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
intrinsic record alone
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to invalidate the claims of the [Asserted Patents.]\u8221\'3f (Dkt. No. 242 at 2) (emphasis in original). The claims of the Asserted Patents are therefore analyzed below to determine whether they contain patent-eligible subject matter, without consideration of the extrinsic evidence provided by Defendants.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I012a831160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I012a831160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I012a831160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I012a831160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
B. Subject Matter Eligibility Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b1 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b1 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b1 \cf25 \f2 \i0 \fs20 \chcbpat2 
}}}
\sb200 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
While the Supreme Court interprets the statutory language of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to \u8220\'3finclude anything under the sun that is made by man,\u8221\'3f long-standing precedent bars the grant of a patent directed to \u8220\'3flaws of nature, physical phenomena, or abstract ideas,\u8221\'3f except for certain circumstances. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1980116775&pubNum=0000780&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_780_309&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_309" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Chakrabarty
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 447 U.S. 303, 309, 100 S.Ct. 2204, 65 L.Ed.2d 144 (1980)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. However, courts are mindful that \u8220\'3fall inventions at some level embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_780_71&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_71" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Labs., Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. 66, 71, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
While a district court may decide patent eligibility at the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 stage, a district court may only conclude that a patent fails to claim patent-eligible subject matter \u8220\'3fwhen there are no factual allegations that, taken as true, prevent resolving the eligibility question as a matter of law.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043808569&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_506_1125&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1125" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Aatrix Software, Inc. v. Green Shades Software, Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 882 F.3d 1121, 1125 (Fed. Cir. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I012b6d7160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I012b6d7160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I012b6d7160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I012b6d7160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. Composition Claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531 Patent
}}}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
 and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035430745&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=Iefc12300b27411e48d3ad255cfb4914b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 046 Patent
}}}
\sb200 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_5_50}{\*\bkmkend co_pp_sp_999_5_50}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*5
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Plaintiff asserts that Defendants are infringing the composition claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035430745&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=Iefc12300b27411e48d3ad255cfb4914b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 046 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Courts may treat claims together for purposes of resolving patentable subject matter where those claims contain the same basic elements. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035137097&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_506_1348&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1348" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Content Extraction & Transmission LLC v. Wells Fargo Bank, Nat\rquote l Ass\rquote n
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 776 F.3d 1343, 1348 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Therefore, Defendants\rquote  proposed representative claim for each patent is used for the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis below.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 1 of the reexamined 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directed to solid supplement formulations:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. A solid supplement formulation comprising: at least one nitrate salt compound; and at least one isolated amino acid compound selected from the group consisting of Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=bdrug&entityId=I396eb006475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
L-Histidine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c673045475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Isoleucine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Leucine, Norvaline, Ornithine, Valine, Aspartic Acid, Cysteine, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=Iffb483c06c7111e18b05fdf15589d8e8&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Glycine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Lysine, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af158f9475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Methionine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Proline, Tyrosine, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3b6b1c91475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Phenylalanine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, wherein the at least one isolated amino acid compound is a separate compound than the at least one nitrate salt compound.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(Dkt. No. 226, Ex. H.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 1 is representative of the composition claims of the reexamined 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035430745&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=Iefc12300b27411e48d3ad255cfb4914b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 046 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. A solid composition comprising: at least one isolated nitrate salt compound; and at least one isolated amino acid compound selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=bdrug&entityId=I396eb006475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
L-Histidine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c673045475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Isoleucine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Leucine, Norvaline, Ornithine, Valine, Aspartic Acid, Cysteine, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=Iffb483c06c7111e18b05fdf15589d8e8&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Glycine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Lysine, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af158f9475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Methionine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Proline, Tyrosine, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3b6b1c91475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Phenylalanine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, wherein the at least one isolated amino acid compound is a separate compound than the at least one nitrate salt compound.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(Dkt. No. 226, Ex. J.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Defendants contend that the composition claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035430745&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=Iefc12300b27411e48d3ad255cfb4914b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 046 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 comprise two chemical compounds: a nitrate salt compound and an amino acid compound. (Dkt. No. 231 at 11.) Defendants further assert that these compounds are the exact same forms that occur naturally in the environment. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 12. Defendants cite 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1948116775&pubNum=0000780&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_780_130&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_130" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Funk Bros. Seed Co. v. Kalo Inoculant Co.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 333 U.S. 127, 130-31, 68 S.Ct. 440, 92 L.Ed. 588 (1948)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for the proposition that mixing different natural phenomena together is insufficient to render an invention patent eligible. (
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1948116775&pubNum=0000780&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiff contends that \u8220\'3fthe combination of a (1) nitrate salt and (2) an isolated amino acid is 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
not
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 found in nature.\u8221\'3f (Dkt. No. 238 at 11.) To support this assertion, Plaintiff points to the description of the synthesis of these compounds in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 specification, stating:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
One example of this comprises creatine nitrate, which the patent explicitly describes is \u8220\'3fsynthesized ... by combining nitric acid and Creatine, mixing with water or another polar, easily evaporated solvent like methanol, alcohol, pyridine, and the like, and leaving to crystallize. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Ex, D, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Col. 9. Another example of a nitrate salt is arginine nitrate, which the patent again describes must be synthesized. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1948116775&pubNum=0000780&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Col. 8. The patents include similar descriptions regarding the need to \u8220\'3fsynthesize\u8221\'3f additional nitrate salts, including Glutamine Nitrate, Leucine Nitrate, Norvaline Nitrate, Ornithine Nitrate, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c963475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Histidine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Nitrate, Beta Alanine Nitrate, and Agmatine Nitrate. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1948116775&pubNum=0000780&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Cols. 8-12.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(Dkt. No. 238 at 11.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In addition, Plaintiff asserts that \u8220\'3feven if nitrate salts could be found in nature, the patent claims \u8220\'3fencompass an 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
overall
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 composition directed to nitrate salts 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
combined
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 with selected \u8216\'3fisolated\u8217\'3f amino acids.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
)(emphasis in original).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_6_50}{\*\bkmkend co_pp_sp_999_6_50}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*6
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Plaintiff further asserts that the Supreme Court has set forth two tests for patent eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
: one for composition claims and one for method claims. (Dkt. No. 238 at 5.) In contrast, Defendants contend that the single two-step 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice/Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 test is controlling for all types of inventions. (Dkt. No. 242 at 4.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court need not weigh in as to whether the patent eligibility tests put forth by the Parties occur as two separate tests, or whether the tests can be merged into one. The result is the same either way. For simplicity and because it is the test asserted by the Defendants as the moving party, all patent claims are analyzed hereafter under the two-step 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice/Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 test.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The composition claims of the instant inventions are analogous to the gunpowder example provided in the United States Patent and Trademark Office\rquote s (USPTO) \u8220\'3fNature Based Products\u8221\'3f Examples.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012047360455_ID0E3PAG_50}{\*\bkmkend co_fnRef_B00012047360455_ID0E3PAG_50}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012047360455_50" }{\fldrslt 
{\super \b0 \cf25 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Dkt. No. 238, Ex. 1.) Similar to the gunpowder example, which provides a patent-eligible composition comprising a combination of three naturally occurring substances, the claimed compositions of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035430745&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=Iefc12300b27411e48d3ad255cfb4914b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 046 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are allegedly not found in nature and are allegedly markedly different from their naturally-occurring counterparts. For example, Plaintiff discusses the differences between naturally occurring creatine and the synthesized creatine nitrate as taught in the Asserted Patents, stating:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Regarding naturally occurring Creatine (as opposed to Creatine Nitrate), the patent explains that \u8220\'3fCreatine, by itself, has no vasodilating properties. Creatine is also water insoluble, which reduces its bioavailability and limits the forms in which Creatine may be effectively used.\u8221\'3f [
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 Patent], Cols. 3-4. But when synthesized as taught by the patents into a nitrate salt such as Creatine Nitrate, it offers critical advantages ...
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(Dkt. No. 238 at 13.) Plaintiff further points to the discussion of the improvements of the claimed combinations found in the Asserted Patents, stating:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
[T]he patents make clear that the claimed combinations are not only different from their naturally occurring counterparts, they offer dramatic improvements over those counterparts, including \u8220\'3fimproved vasodilation effects,\u8221\'3f \u8220\'3fbetter circulation and distribution,\u8221\'3f vastly improved water solubility, and improved effectiveness with a smaller dose, as well as 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fsubstantially increase[d] ... concentration of an amino acid in the target muscles.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Ex. D, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Cols. 19, 26.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(Dkt. No. 238 at 16.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Therefore, at the motion to dismiss stage, Plaintiff has set forth sufficient facts, if taken as true, that the compositions of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035430745&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=Iefc12300b27411e48d3ad255cfb4914b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 046 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are markedly different from any naturally occurring counterparts, and thus are not directed to one of the judicially recognized exceptions to patent-eligible subject matter (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a law of nature, natural phenomenon, or abstract idea). Because the Asserted Patents are patent eligible under the first step of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice/Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 test, the Court need not address the second step of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice/Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 framework. Plaintiff ThermoLife has shown a plausible entitlement to relief, and dismissal at this stage would be improper. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012293296&pubNum=0000780&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_780_555&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_555" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bell Atl. Corp. v. Twombly
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 550 U.S. 544, 555, 570, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I013642e160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I013642e160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I013642e160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I013642e160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2. Method Claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030808758&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=Ibd230671d88711e2a447f9a5042dbbad&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 187 Patent
}}}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027742370&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I3e30d940a43b11e1ba4083eae598aa4c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 288 Patent
}}}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027694181&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I887a68c09f4c11e1910adc00900fed44&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 572 Patent
}}}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
, and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531 Patent
}}}
\sb200 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_7_50}{\*\bkmkend co_pp_sp_999_7_50}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*7
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Plaintiff asserts that Defendants are infringing the method claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030808758&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=Ibd230671d88711e2a447f9a5042dbbad&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 187 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027742370&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I3e30d940a43b11e1ba4083eae598aa4c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 288 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027694181&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I887a68c09f4c11e1910adc00900fed44&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 572 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. For purposes of resolving patentable subject matter for the methods claims of the Asserted Patents, Defendants\rquote  proposed representative claim for each patent is used for the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis below.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 7 of the reexamined 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030808758&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=Ibd230671d88711e2a447f9a5042dbbad&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 187 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is representative of the athletic performance claims:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
7. A method for increasing athletic performance in a human or animal, the method comprising administering to the human or animal a pharmaceutically effective amount of an amino acid composition comprising at least one constituent selected from the group consisting of a salt of a nitrate (NO
}
{\b0 \cf1 \f2 \i0 \fs16 
{\sub \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
-
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
), a mixed salt of a nitrate (NO
}
{\b0 \cf1 \f2 \i0 \fs16 
{\sub \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
-
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
), a salt of a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iab56f816475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
nitrite
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (NO
}
{\b0 \cf1 \f2 \i0 \fs16 
{\sub \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
-
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
), and a mixed salt of a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iab56f816475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
nitrite
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (NO
}
{\b0 \cf1 \f2 \i0 \fs16 
{\sub \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
-
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
); and Creatine.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(Dkt. No. 226, Ex. I.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027742370&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I3e30d940a43b11e1ba4083eae598aa4c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 288 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is representative of the method claims in the reexamined 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027742370&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I3e30d940a43b11e1ba4083eae598aa4c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 288 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. A method for increasing the bioabsorption of amino acids in a human, the method comprising administering orally to the human a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate of an amino acid selected from the group consisting of: Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=bdrug&entityId=I396eb006475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
L-Histidine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c673045475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Isoleucine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Leucine, Norvaline, Ornithine and Valine.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(Dkt. No. 226, Ex. II.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027694181&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I887a68c09f4c11e1910adc00900fed44&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 572 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is representative of the method claims in the reexamined 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027694181&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I887a68c09f4c11e1910adc00900fed44&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 572 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. A method for increasing the vasodilative characteristics in a human, the method comprising administering orally to the human a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate of an amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=bdrug&entityId=I396eb006475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
L-Histidine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c673045475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Isoleucine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Leucine, Norvaline, Ornithine and Valine.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(Dkt. No. 226, Ex. G.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 2 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is representative of the method claims in the reexamined 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2. A method for increasing bioabsorption of Amino Acids in a human, the method comprising administering to the human a pharmaceutically effective amount of a solid supplement formulation comprising: at least one nitrate salt compound; and at least one isolated amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=bdrug&entityId=I396eb006475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
L-Histidine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c673045475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Isoleucine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Leucine, Norvaline, Ornithine, Valine, Aspartic Acid, Cysteine, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=Iffb483c06c7111e18b05fdf15589d8e8&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Glycine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Lysine, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af158f9475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Methionine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Proline, Tyrosine, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3b6b1c91475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Phenylalanine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, wherein the at least one isolated amino acid compound is a separate compound than the at least one nitrate salt compound.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(Dkt. No. 226, Ex. H)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Defendants contend that the focus of the method claims is the administration of a nitrate salt (or a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iab56f816475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
nitrite
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 salt) and an amino acid compound, which are naturally occurring. (Dkt. No. 231 at 18.) Defendants further assert that increased athletic performance from nitrate consumption is a natural law that cannot receive patent protection. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) This \u8220\'3fnaturally occurring\u8221\'3f argument fails for the reasons described, supra, with regard to the composition claims.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiff further responds that the method claims in the Asserted Patents are directed to \u8220\'3ftreating a human with the recited formulations to increase athletic performance.\u8221\'3f (Dkt. No. 238 at 19-20.) The Special Master finds this argument carries the day, and the methods, as described, are patent eligible.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_8_50}{\*\bkmkend co_pp_sp_999_8_50}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*8
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The USPTO recently issued guidance for determining patent eligibility of method of treatment claims in light of the Federal Circuit decision in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda Pharms. Inc. v. West-Ward Pharms.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 887 F.3d 1117 (Fed. Cir. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In the memorandum, the USPTO states that \u8220\'3fthe Federal Circuit held the claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patent eligible under the first step of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice/Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 framework, because the claims \u8216\'3fare directed to a method of using iloperidone to treat 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,\u8217\'3f rather than being \u8216\'3fdirected to\u8217\'3f a judicial exception.\u8221\'3f USPTO Memorandum on Subject Matter Eligibility Decision: 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda Pharms. Inc. v. West-Ward Pharms.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, June 7, 2018, at page 2, available at https://www.uspto.gov/sites/default/files/documents/memo-vanda-20180607.PDF.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Both Parties agree that the method claims are subject to the two-step 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice/Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 inquiry for determining patent eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Similar to the eligible method claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which cover the administration of a substance to a human subject to cause a change in condition, the method claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030808758&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=Ibd230671d88711e2a447f9a5042dbbad&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 187 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027742370&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I3e30d940a43b11e1ba4083eae598aa4c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 288 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027694181&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I887a68c09f4c11e1910adc00900fed44&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 572 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030657732&pubNum=0004074&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=PA&docFamilyGuid=I03a10290cd4411e2863ad7281712f02b&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 531 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are directed to new and useful methods for treating humans, and are thus patent eligible.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Therefore, at the motion to dismiss stage, Plaintiff has set forth sufficient facts, if taken as true, that the method claims are directed to methods of using the compositions to improve athletic performance, and thus are not directed to one of the judicial exceptions (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a law of nature, natural phenomenon, or abstract idea). Because the Asserted Patents are patent eligible under the first step of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice/Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 test, the Court need not address the second step of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice/Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 framework. Plaintiff ThermoLife has shown a plausible entitlement to relief, and dismissal at this stage would be improper. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012293296&pubNum=0000780&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=RP&fi=co_pp_sp_780_555&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_555" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bell Atl. Corp. v. Twombly
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 550 U.S. 544, 555, 570, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I013c0f4160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I013c0f4160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I013c0f4160c111eb8bc6b342c618e}{\*\bkmkend co_anchor_I013c0f4160c111eb8bc6b342c618e}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
IV. CONCLUSION
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Accordingly, it is recommended that Defendants\rquote  Motion to Dismiss for Failure to State a Claim (Dkt. No. 231) be DENIED. This matter is suitable for decision without oral argument, and it is therefore recommended that Defendants\rquote  Motion for Oral Argument (Dkt. No. 243) be DENIED.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf29 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_50}{\*\bkmkend co_allCitations_50}
{\b1 \cf29 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Not Reported in Fed. Supp., 2018 WL 7077163
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012047360455_50}{\*\bkmkend co_footnote_B00012047360455_50}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012047360455_ID0E3PAG_50" }{\fldrslt 
{\super \b0 \cf25 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf25 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The USPTO has provided extensive guidance and numerous examples to guide patent examiners in determining patent eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I6dfffa101ca311e9aec5b23c3317c9c0&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Section
}
}
}
{\b0 \cf25 \f3 \i0 \fs18 \chcbpat2 
}
{\b0 \cf25 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf25 \f3 \i0 \fs18 \chcbpat2 
}\b0 \cf25 \f3 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. Of particular relevance to the claims of the Asserted Patents here, the USPTO has provided a number of example claims related to \u8220\'3fNature-Based Products\u8221\'3f.
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Dkt. No. 238, Ex. 1.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf22 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf22 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf22 \f3 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf22 \f3 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf22 \f3 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf22 \f3 \ri29 \i0 \fs19 \li29 
{\b0 \cf22 \f3 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf22 \f3 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }